Sonia Tugues

Sonia Tugues

Auto-generated profile, based on publicly available information

Sonia Tugues

Innate Lymphoid Cells and Cancer, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2014 in Cell Death & Differentiation
Verified
Journal Article
Closed access
STS Tugues
S Tugues
SBS H Burkhard
S H Burkhard
IOI Ohs
I Ohs
MVM Vrohlings
M Vrohlings
KNK Nussbaum
K Nussbaum
BBB Becher
B Becher

28 June 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
LDLaura Ducimetière
Laura Ducimetière
GLGiulia Lucchiari
Giulia Lucchiari
GLGioana Litscher
Gioana Litscher
MNMarc Nater
Marc Nater
LHLaura Heeb
Laura Heeb
STSonia Tugues
Sonia Tugues
Significance: Innate lymphoid cells hold great promise for the treatment of metastases. Development of effective therapies based on these versatile immune cells, however, is hampered by our limited knowledge of their behavior in the metastatic niche. Here, we describe that defense against liver metastasis requires collaboration between two innate lymphocyte subsets, conventional NK cells (cNKs) and tissue-resident type I innate lymphoid cells (trILC1s). We show that different cancers generate their own particular metastatic niche–inducing specific changes in cNKs and trILC1s. Furthermore, we uncover specific cNK subsets that can be manipulated to improve their antimetastatic potential. Our work contributes to understanding how cancer-specific factors and hepatic innate lymphocytes exert mutual influence and how this can be exploited for therapeutic purposes.

14 December 2017 in Cancer Research
Verified
Journal Article
Open access
PDF file
IOIsabel Ohs
Isabel Ohs
LDLaura Ducimetière
Laura Ducimetière
JMJoana Marinho
Joana Marinho
PKPaulina Kulig
Paulina Kulig
BBBurkhard Becher
Burkhard Becher
STSonia Tugues
Sonia Tugues
Immune checkpoint therapies target tumor antigen-specific T cells, but less is known about their effects on natural killer (NK) cells, which help control metastasis. In studying the development of lung metastases, we found that NK cells lose their cytotoxic capacity and acquire a molecular signature defined by the expression of coinhibitory receptors. In an effort to overcome this suppressive mechanism, we evaluated NK cell responses to the immunostimulatory cytokine IL12. Exposure to IL12 rescued the cytotoxicity of NK cells but also led to the emergence of an immature NK cell population that expressed high levels of the coinhibitory molecules PD-1, Lag-3, and TIGIT, thereby limiting NK cell–mediated control of pulmonary metastases. Notably, checkpoint blockade therapy synergized with IL12 to fully enable tumor control by NK cells, demonstrating that checkpoint blockers are not only applicable to enhance T cell–mediated immunotherapy, but also to restore the tumor-suppressive capacity of NK cells. Cancer Res; 77(24); 7059–71. ©2017 AACR.

28 November 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
STSonia Tugues
Sonia Tugues
AAAna Amorim
Ana Amorim
SSSabine Spath
Sabine Spath
GMGuillaume Martin-Blondel
Guillaume Martin-Blondel
BSBettina Schreiner
Bettina Schreiner
BBBurkhard Becher
Burkhard Becher
Myeloid cells mediate GvHD immunopathology, whereas GvL relies on T cell cytotoxicity.

1 April 2021 in Cell Reports
Verified
Journal Article
Open access
CTCarlotta Tacconi
Carlotta Tacconi
CCCatharina D. Commerford
Catharina D. Commerford
LDLothar C. Dieterich
Lothar C. Dieterich
SSSimon Schwager
Simon Schwager
YHYuliang He
Yuliang He
MDMichael Detmar
Michael Detmar
Although the contribution of macrophages to metastasis is widely studied in primary tumors, the involvement of macrophages in tumor-draining lymph nodes (LNs) in this process is less clear. We find CD169+ macrophages as the predominant macrophage subtype in naive LNs, which undergo proliferative expansion in response to tumor stimuli. CD169+ LN macrophage depletion, using an anti-CSF-1R antibody or clodronate-loaded liposomes, leads to increased metastatic burden in two mouse breast cancer models. The expansion of CD169+ macrophages is tightly connected to B cell expansion in tumor-draining LNs, and B cell depletion abrogates the effect of CD169+ macrophage absence on metastasis, indicating that the CD169+ macrophage anti-metastatic effects require B cell presence. These results reveal a protective role of CD169+ LN macrophages in breast cancer metastasis and raise caution for the use of drugs aiming at the depletion of tumor-associated macrophages, which might simultaneously deplete macrophages in tumor-draining LNs.

1 June 2013 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
STSònia Tugues
Sònia Tugues
SHSatoshi Honjo
Satoshi Honjo
CKChristian König
Christian König
NPNarendra Padhan
Narendra Padhan
JKJeffrey Kroon
Jeffrey Kroon
LCLena Claesson-Welsh
Lena Claesson-Welsh
CD63 is a member of the transmembrane-4 glycoprotein superfamily (tetraspanins) implicated in the regulation of membrane protein trafficking, leukocyte recruitment, and adhesion processes. We have investigated the involvement of CD63 in endothelial cell (EC) signaling downstream of β1 integrin and VEGF. We report that silencing of CD63 in primary ECs arrested capillary sprouting and tube formation in vitro because of impaired adhesion and migration of ECs. Mechanistically, CD63 associated with both β1 integrin and the main VEGF receptor on ECs, VEGFR2. Our data suggest that CD63 serves to bridge between β1 integrin and VEGFR2 because CD63 silencing disrupted VEGFR2-β1 integrin complex formation identified using proximity ligation assays. Signaling downstream of β1 integrin and VEGFR2 was attenuated in CD63-silenced cells, although their cell surface expression levels remained unaffected. CD63 was furthermore required for efficient internalization of VEGFR2 in response to VEGF. Importantly, systemic delivery of VEGF failed to potently induce VEGFR2 phosphorylation and downstream signaling in CD63-deficient mouse lungs. Taken together, our findings demonstrate a previously unrecognized role for CD63 in coordinated integrin and receptor tyrosine kinase signaling in vitro and in vivo.